Abstract
Clinical ThyroidologyVol. 33, No. 8 HyperthyroidismThyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy AdministeredUlla Feldt-RasmussenUlla Feldt-RasmussenDepartment of Medical Endocrinology and Metabolism, Rigshospitalet (Copenhagen University Hospital) and Department of Clinical Medicine, Faculty of Health and Medical Science, Copenhagen University, Copenhagen, DenmarkSearch for more papers by this authorPublished Online:6 Aug 2021https://doi.org/10.1089/ct.2021;33.350-353AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 33Issue 8Aug 2021 InformationCopyright 2021 American Thyroid Association, Inc.To cite this article:Ulla Feldt-Rasmussen.Thyroid-Stimulating Hormone Receptor Antibodies in Refractory Graves’ Disease Change Differently According to the Type of Definitive Therapy Administered.Clinical Thyroidology.Aug 2021.350-353.http://doi.org/10.1089/ct.2021;33.350-353Published in Volume: 33 Issue 8: August 6, 2021PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
